Paloma Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

Paloma Partners’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-26,456	Closed	-$151K	–	2265
2015 Q4	$151K	Buy	+26,456	New	+$142K	﹤0.01%	1582

Other funds holding SVA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

USAA

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

PRCM

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paloma Partners's SVA Position: Q1 2016 in Review

Paloma Partners sold out of Sinovac Biotech, Ltd (SVA) in Q1 2016, closing a stake of 26,456 shares — an estimated $151K sold.

Paloma Partners first reported a position in SVA in Q4 2015 and held it in 1 quarter. The position peaked at $151K in Q4 2015. 34 funds tracked by Wall St. Rank hold SVA as of Q1 2016.

Paloma Partners reported no remaining Sinovac Biotech, Ltd position as of Q1 2016 after selling out during the quarter.
Paloma Partners sold 26,456 Sinovac Biotech, Ltd shares in Q1 2016, an estimated $151K.
Paloma Partners first reported a position in Sinovac Biotech, Ltd in Q4 2015 and held it in 1 quarter.
Paloma Partners's Sinovac Biotech, Ltd position peaked at $151K in Q4 2015.
34 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2016.

Based on Paloma Partners's 13F filing for Q1 2016, filed 16 May 2016.